Destiny Pharma PLC (DEST)

15.75 +0.75 (+4.76%)
Closed GBP Disclaimer

Destiny Pharma PLC Company Profile

Sector
Healthcare
Employees
24
Equity Type
ORD
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Contact Information
Address
Science Park Square Falmer Brighton,BN1 9SB United Kingdom
Phone
44 1273 704440
Fax
-
Top Executives
Name
Age
Since
Title
Richard Proctor 0 2018 Member of Scientific Advisory Board
Vance Garrison Fowler 0 2018 Member of Scientific Advisory Board
Glenn J. R. Whitman 0 2018 Member of Scientific Advisory Board
Leonard Alan Mermel 0 2018 Member of Scientific Advisory Board
Nigel Stanley Brooksby 72 2022 Non-Executive Director
E Patchen Dellinger 0 0000 Member of Scientific Advisory Board
James Patrick Stearns 44 2022 Non-Executive Director
Mark H. Wilcox 0 2021 Member of Scientific Advisory Board
Dale N. Gerding 0 2020 Member of Scientific Advisory Board
Shaun Claydon 56 2018 CFO, Company Secretary & Director
William Guy Love 62 1997 Founder, Chief Scientific Officer & Director
Debra Barker 62 2020 Interim CMO & Senior Independent Director
Christopher John Tovey 59 2023 CEO & Director
Aled Paton Williams 54 2022 Independent Non-Executive Director
Anthony Nigel Russell Rudd 78 2016 Independent Chairman
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.